The U.S. stock market recently experienced a significant downturn, with major indices such as the Nasdaq and S&P 500 closing sharply lower, driven by a notable decline in technology shares. In this environment of heightened volatility and economic uncertainty, identifying high-growth tech stocks requires careful consideration of their potential for innovation and resilience amidst broader market fluctuations.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| ADMA Biologics | 20.01% | 24.80% | ★★★★★☆ |
| Exelixis | 10.68% | 20.92% | ★★★★★☆ |
| Palantir Technologies | 26.87% | 29.45% | ★★★★★★ |
| Workday | 11.19% | 32.11% | ★★★★★☆ |
| Circle Internet Group | 26.50% | 88.24% | ★★★★★☆ |
| RenovoRx | 65.52% | 68.63% | ★★★★★☆ |
| Gorilla Technology Group | 32.75% | 122.61% | ★★★★★☆ |
| OS Therapies | 56.64% | 68.61% | ★★★★★☆ |
| Zscaler | 15.72% | 40.94% | ★★★★★☆ |
| Procore Technologies | 11.61% | 114.49% | ★★★★★☆ |
Click here to see the full list of 73 stocks from our US High Growth Tech and AI Stocks screener.
Let's review some notable picks from our screened stocks.
Gyre Therapeutics (GYRE)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Gyre Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing small-molecule drugs for treating organ fibrosis, with a market cap of $758.03 million.
Operations: Gyre focuses on developing and commercializing small-molecule drugs targeting organ fibrosis, generating revenue primarily through its Gyre Pharmaceuticals segment, which reported $107.27 million. The company is engaged in the anti-inflammatory and anti-fibrotic drug market, reflecting its commitment to addressing organ fibrosis.
Gyre Therapeutics, recently added to the S&P Global BMI Index, showcases robust growth with a 26% annual increase in revenue and an impressive 49.3% surge in earnings. This performance is particularly notable given the broader US market averages of 10.4% and 16%, respectively. Despite challenges such as supply chain disruptions impacting its Etorel rollout, the company's strategic moves, including successful Phase 3 trials of Pirfenidone for pneumoconiosis treatment in China, underline its innovative edge and potential for sustained growth amidst industry uncertainties.
- Navigate through the intricacies of Gyre Therapeutics with our comprehensive health report here.
Examine Gyre Therapeutics' past performance report to understand how it has performed in the past.
Kiniksa Pharmaceuticals International (KNSA)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company that develops and commercializes novel therapies for diseases with unmet needs, focusing on cardiovascular indications globally, with a market cap of $3.08 billion.
Operations: Kiniksa Pharmaceuticals generates revenue primarily from developing and delivering therapeutic medicines, amounting to $597.97 million. The company focuses on cardiovascular indications as part of its strategy to address diseases with unmet needs globally.
Kiniksa Pharmaceuticals International has demonstrated remarkable financial resilience and growth, with a significant turnaround in its financial health as evidenced by the latest quarterly results. The firm reported a substantial increase in revenue to $180.86 million from $112.21 million year-over-year and shifted from a net loss of $12.69 million to a net income of $18.44 million for Q3 2025. This performance is underscored by an upward revision in full-year sales guidance, now projected between $670 million and $675 million, indicating robust demand for its offerings and effective management execution amid dynamic market conditions. These financial metrics are complemented by Kiniksa's strategic presence at major healthcare conferences, enhancing its industry stature and investor confidence.
Savara (SVRA)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Savara Inc. is a clinical-stage biopharmaceutical company dedicated to developing treatments for rare respiratory diseases, with a market cap of $994.24 million.
Operations: Savara Inc. is focused on developing therapies for rare respiratory diseases, operating as a clinical-stage biopharmaceutical entity. The company does not currently generate revenue from product sales.
Savara Inc., amidst a challenging financial period marked by increasing net losses, reported a significant third-quarter loss of $29.56 million, deepening from $24.25 million the previous year. Despite these setbacks, the company remains active in industry conferences and recently raised approximately $130 million through equity offerings, underscoring its proactive approach to funding and innovation. This strategic maneuvering is critical as Savara continues to invest in R&D for advanced treatments like molgramostim for autoimmune pulmonary alveolar proteinosis, showcasing its commitment to addressing rare respiratory diseases with potential breakthrough therapies.
Make It Happen
- Navigate through the entire inventory of 73 US High Growth Tech and AI Stocks here.
- Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
- Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.
Ready To Venture Into Other Investment Styles?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Kiniksa Pharmaceuticals International might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com